Skip to main content
SpringerLink
Log in
Book cover

Zukunftsperspektiven in Psychiatrie und Psychotherapie pp 73–86Cite as

Künftige Entwicklung der Psychopharmakotherapie

  • Conference paper

  • 45 Accesses

Zusammenfassung

Die Psychopharmakologie gilt heute als ein eigenständiger Forschungsbereich innerhalb der Neurowissenschaften. Unter der Bezeichnung Psychopharmaka werden eine Vielzahl unterschiedlicher Gruppen von Arzneimitteln zusammengefasst, die zur Behandlung psychischer Störungen dienen. Dazu zählen Anti- psychotika, Antidepressiva, Tranquilizer und Hypnotika, Psychostimulanzien sowie Nootropika bzw. Antidementiva. Pflanzliche Präparate (Phytopharmaka), wie das antidepressiv wirksame Johanniskraut, erfreuen sich zunehmender Beliebtheit. Dieser Beitrag versucht, in der gebotenen Kürze, streiflichtartig die wichtigsten aktuellen und zukünftigen Entwicklungen in der Psychopharmakologie störungsbezogen darzustellen.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ator N and Kautz M (2000) Differentiating benzodiazepine and — barbiturate — like discriminative stimulus effects of lorazepam, diazepam, pentobarbital, imidazenil and zaleplon in two-versus three-lever procedures. Behavioural Pharmacology 11: 1–14

    Article  PubMed  CAS  Google Scholar 

  2. Busto U, Naranjo C, Bremner K, Peachey J, Bologa M (1998) Safety of ipsapirone treatment compared with lorazepam: discontinuation effects. J Psychiatry Neurosci 23: 35–44

    PubMed  CAS  Google Scholar 

  3. Dautzenberg F, Wichmann J, Higelin J, Py-Lang G, Kratzeisen C, Malherbe P, Kilpatrick G, Jenck F (2001) Pharmacological characterization of the novel nonpeptide orphanin FQ/noci-ceptin receptor agonist Ro 64-6198: rapid and reversible desensitization of the ORL1 receptor in vitro and lack of tolerance in vivo. The Journal of Pharmacology and Experimental Therapeutics 298: 812–819

    PubMed  CAS  Google Scholar 

  4. DeVane C (2000) Pharmacologic characteristics of ideal antidepressants in the 21st century. J Clin Psychiatry 61(Suppl 11): 4–8

    PubMed  CAS  Google Scholar 

  5. Helmuth L (2000) An antibiotic to treat Alzheimer’s. Science 290: 1273–1274

    Article  PubMed  CAS  Google Scholar 

  6. Hirai S (2000) Alzheimer Disease: current therapy and future therapeutic strategies. Alzheimer Disease and Associated Disorders 14(Suppl 1): 11–17

    Article  Google Scholar 

  7. Marx J (2001) New leads on the, how’ of Alzheimer’s. Science 293: 2192–2194

    Article  PubMed  CAS  Google Scholar 

  8. Morrow B, Elsworth J, Lee E, Roth R (2000) Divergent effects of putative anxiolytics on stress-induced Fos expression in the mesoprefrontal system of the rat. Synapse 36: 143–154

    Article  PubMed  CAS  Google Scholar 

  9. Müller-Spahn F (1999) Psychopharmaka. Therapeutische Umschau 56: 719–725

    Article  PubMed  Google Scholar 

  10. Pacher P, Kohegyi E, Kecskemeti V, Furst S (2001) Current trends in the development of new antidepressants. Current Medical Chemistry 8: 89–100

    Article  CAS  Google Scholar 

  11. Revel L, Mennuni L, Garofalo P, Makovec F (1998) CR 2945: a novel CCKb receptor antagonist with anxiolytic-like activity. Behavioural Pharmacology 9: 183–194

    PubMed  CAS  Google Scholar 

  12. Scatton B and Sanger D (2000) Pharmacological and molecular targets in the search for novel antipsychotics. Behavioural Pharmacology 11: 243–256

    Article  PubMed  CAS  Google Scholar 

  13. Schenk D, Barbour R, Dunn W, Gordon G et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease like pathology in the PDAPP mouse. Nature 400: 173–177

    Article  PubMed  CAS  Google Scholar 

  14. Skutella T, Probst J, Renner U, Holsboer F, Behl C (1998) Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety. Neuroscience 85: 95–805

    Article  Google Scholar 

  15. Tallman J (2000) Development of novel antipsychotic drugs. Brain Research Reviews 31: 385–390

    Article  PubMed  CAS  Google Scholar 

  16. Wilkinson D (2001) Drugs for treatment of Alzheimer’s disease. Int J Clin Pract 55(2): 129–134

    PubMed  CAS  Google Scholar 

  17. Winkler D und Jucker M (2001) Schon gegen Alzheimer geimpft? — Mechanismen zerebraler Amyloidosen. Schweiz Med Forum 28: 745–749

    Google Scholar 

Download references

Authors
  1. Prof. Dr. F. Müller-Spahn
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Rheinische Kliniken Düsseldorf, Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität Düsseldorf, Bergische Landstraße 2, 40629, Düsseldorf, Germany

    Wolfgang Gaebel

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Müller-Spahn, F. (2002). Künftige Entwicklung der Psychopharmakotherapie. In: Gaebel, W. (eds) Zukunftsperspektiven in Psychiatrie und Psychotherapie. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-57392-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57392-7_8

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-63255-6

  • Online ISBN: 978-3-642-57392-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation